Recent Updates
Recently added Catalysts
BGM Positive Sentiment Score: 70/100

Qilian Received a Letter from Nasdaq Related to Regain Compliance

Key Takeaway: Qilian International Holding Group Ltd received a letter from NASDAQ confirming that it is now in compliance with listing rules after having filed its annual report on Form 20-F. The company had previously faced non-compliance issues due to a delay in the 2022 report submission. Following the timely filing on April 19, 2023, NASDAQ reassured the company of its compliance status. This is crucial for Qilian as it ensures continued trading on the NASDAQ stock exchange.

Market Sentiment Analysis

POSITIVE FACTORS

  • Qilian has filed its Form 20-F on time, regaining NASDAQ compliance.
  • NASDAQ has confirmed Qilian's compliance with its listing rules.
  • The company can continue trading on NASDAQ without restrictions.

Full Press Release Details

Qilian Received a Letter from Nasdaq Related
to Regain Compliance
JIUQUAN, China, April 26, 2023 /PRNewswire/ - Qilian International
Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer,
previously announced that on February 16, 2023, it received a written notice (the "Notice") from the Listing Qualifications
Department of The Nasdaq Stock Market ("NASDAQ") indicating that the Company was not in compliance with NASDAQ Listing Rule
5250(c)(1) for continued listing (the "Rule") as a result of not having timely filed its annual report on Form 20-F for the
year ended September 30, 2022.
On April 19, 2023, the Company filed the Form 20-F, and on April 20,
2023, the Company received a second letter from NASDAQ stating that based on the April 19, 2023 filing of the Company's Form 20-F,
NASDAQ has determined that the Company complies with the Rule. Accordingly, NASDAQ informed the Company that it now considers this matter
About Qilian International Holding Group Ltd
Qilian International Holding Group Ltd, headquartered in Gansu, China,
is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice
products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers.
The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at http://ir.qlsyy.net.
Forward Looking Statements
This press release contains forward-looking statements as defined by
the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical
facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters,
it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties
that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These
statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the
Company's future business development; products demand and acceptance; changes in technology; economic conditions; reputation and brand;
the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China; the
COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained
in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's
filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation
to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For media enquiries, please contact: Yubin
SOURCE Qilian International Holding Group Ltd

Frequently Asked Questions

Why did Qilian receive a letter from Nasdaq?

Qilian received a letter for not complying with NASDAQ Rule 5250(c)(1) due to a delayed annual report.

How did Qilian respond to the Nasdaq notice?

Qilian filed its Form 20-F on April 19, 2023, addressing the compliance issue.

What was NASDAQ's response after Qilian's filing?

NASDAQ informed Qilian on April 20, 2023, that it now complies with the listing rule.

What does Qilian International manufacture?

Qilian manufactures pharmaceutical and chemical products, including licorice and oxytetracycline.

In how many provinces does Qilian sell its products?

Qilian sells its products in more than 20 provinces across China.

Last updated: Apr 26, 2023